Transcriptional response of vaginal epithelial cells to medroxyprogesterone acetate treatment results in decreased barrier integrity.
Cell Line
Cell Membrane Permeability
/ drug effects
Contraceptive Agents, Female
/ adverse effects
Disease Susceptibility
/ chemically induced
Epithelial Cells
/ cytology
Estradiol
/ adverse effects
Female
Gene Expression Profiling
HIV Infections
/ immunology
HIV-1
/ immunology
Humans
Medroxyprogesterone Acetate
/ adverse effects
Progesterone
/ adverse effects
Transcription, Genetic
/ drug effects
Transcriptome
/ drug effects
Vagina
/ cytology
Estradiol
HIV-1
Medroxyprogesterone acetate
Progesterone
Vaginal epithelial cells
Journal
Journal of reproductive immunology
ISSN: 1872-7603
Titre abrégé: J Reprod Immunol
Pays: Ireland
ID NLM: 8001906
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
received:
21
07
2020
revised:
12
11
2020
accepted:
19
11
2020
pubmed:
8
12
2020
medline:
6
11
2021
entrez:
7
12
2020
Statut:
ppublish
Résumé
Medroxyprogesterone acetate (MPA) is a frequently used hormonal contraceptive that has been shown to significantly increase HIV-1 susceptibility by approximately 40 %. However, the underlying mechanism by which this occurs remains unknown. Here, we examined the biological response to MPA by vaginal epithelial cells, the first cells to encounter HIV-1 during sexual transmission, in order to understand the potential mechanism(s) of MPA-mediated increase of HIV-1 infection. Using microarray analysis and in vitro assays, we characterized the response of vaginal epithelial cells, grown in biologically relevant air-liquid interface (ALI) cultures, to physiological levels of female sex hormones, estradiol (E2), progesterone (P4), or MPA. Transcriptional profiling of E2, P4 or MPA-treated vaginal epithelial cells indicated unique transcriptional profiles associated with each hormone. MPA treatment increased transcripts of genes related to cholesterol/sterol synthesis and decreased transcripts related to cell division and cell-cell adhesion, results not seen with E2 or P4 treatments. MPA treatment also resulted in unique gene expression indicative of decreased barrier integrity. Functional assays confirmed that MPA, but not E2 or P4 treatments, resulted in increased epithelial barrier permeability and inhibited cell cycle progression. The effects of MPA on vaginal epithelial cells seen in this study may help explain the increase of HIV-1 infection in women who use MPA as a hormonal contraceptive.
Identifiants
pubmed: 33285485
pii: S0165-0378(20)30174-1
doi: 10.1016/j.jri.2020.103253
pii:
doi:
Substances chimiques
Contraceptive Agents, Female
0
Progesterone
4G7DS2Q64Y
Estradiol
4TI98Z838E
Medroxyprogesterone Acetate
C2QI4IOI2G
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
103253Subventions
Organisme : CIHR
ID : FRN126019
Pays : Canada
Organisme : CIHR
ID : FRN138657
Pays : Canada
Informations de copyright
Copyright © 2020 The Authors. Published by Elsevier B.V. All rights reserved.